Cure pharmaceutical augments its existing u.s. dea license in order to initiate development of its psychedelics-based pharmaceutical clinical pipeline

Oxnard, calif.--(business wire)--cure pharmaceutical holding corp. (“cure” or the “company”) (otc: curr), a vertically integrated drug delivery and product development company, announced today that it has secured an extension to its schedule i u.s. drug enforcement agency (dea) license that will allow the company to conduct research on psychedelics-based pharmaceuticals using compounds such as lsd, mdma, and psilocybin as potential treatments for various mental health disorders. the license ena
CURR Ratings Summary
CURR Quant Ranking